Oragenics Inc. · AMEX:OGEN
Oragenics — Investor Presentation (January 2026)
17 slides from Oragenics's investor presentation, Jan 20, 2026
Slide 1: Transforming Concussion Care with Innovative Intranasal Delivery
ICS Transforming Concussion Care with Innovative Intranasal Delivery The first potential FDA-approved therapy for concussion. N NYSE AMERICAN: OGEN WINTER 2025/2026
Slide 2: Forward Looking Statements
Forward Looking Statements This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information curren
Slide 3: Brain-First Neurotherapeutics
Brain-First Neurotherapeutics Pioneering a New Standard of Care for Concussion First-in-class Intranasal direct- Entering Phase 2 Massive TAM in Expert leaders; neurosteroid for to-brain delivery trials; clear FDA target markets renowned concussion (mTBI) pathway scientists nN li AR RR pee NYSE Amer
Slide 4: Investment Highlights
First & only neurotherapeutic for most prominent neurological condition without an FDA- approved solution + Expanding IP Portfolio and new chemical entity (NCE) designation Zero competition in massive markets for concussion and mild traumatic brain injury (mTBI) | nve st mM e nt + 69M concussions an
Slide 5: Management Team
Janet Huffman | Chief Executive Officer & Chief Financial Officer CFO for Nasdaq-listed TRXADE HEALTH (Scienture Holdings); founding member, CFO for Banyan Pediatric Care Centers, leading merger with Assisted 4 Living (Arboreta Healthcare Inc.); CFO for Signature HomeNow. James P. Kelly, MA, MD, FAA
Slide 6: Massive Markets, Zero Competition
Massive Markets, Zero Competition Concussion Market by 2027" Nasal drug delivery market by 2030° * 69 million concussions annually worldwide * ZERO FDA-approved phi macological * 75-90% of ER visits for head injury involved treatments for concussion concussion worldwide* * Oragenics positioned to ow
Slide 7: Unmet Medical Need for Concussion
Unmet Medical Need for Mild traumatic brain injury (mTBI) affecting 69M annually worldwide * Symptoms: Headache, confusion, dizziness, memory problems, nausea * Risk: 30-80% develop post-concussion syndrome; increased dementia risk Motor Vehicles * "Rest, observe, wait" = symptom management only 17%
Slide 8: ONP-002: Phase 2 Lead Asset
ONP- 002: Phase 2 Lead Asset NYSE American: OGEN . ONLY pharmacological treatment in clinical development with FDA pathway for acute concussion First-in-class intranasal neurosteroid Intellectual property protection through 2040+ Reduces swelling, inflammation, oxidative stress Targets the biology o
Slide 9: Delivery Pathway and Biological Action
Delivery Pathway: * Delivered via custom intranasal device * Travels through olfactory pathway directly to brain * Fast-acting with low systemic exposure Biological Action: * Preserves blood-brain barrier integrity * Promotes cell survival and neuroprotection Reduces inflammation and oxidative stres
Slide 10: The Direct-to-Brain Delivery
The Direct-to-Brain [ Lung Protection Direct Brain Access 1 Esophagus Non-Invasive Protection Field Use 1 [ Lightweight Emergency Portable Settings
Slide 11: ONP-002 Phase 1 Results
ORAGENICS ONP-002: Phase | Single and Multiple Ascending Dose (SAD/MAD) safety study of ONP-002: * Neuroprotective molecular and behavioral effects within hours Pharmacokinetic profile confirms minimal systemic exposure Excellent safety profile with zero severe adverse events; well-tolerated across
Slide 12: Strategic Phase 2a Trial Design
Strategic Phase 2 Trial Design Study De: Enrollment Criteria Primary Endpoints T scan negative for structural brain * Safety: Adverse events, nasal injury examinations * Presenting symptoms: headache, loss of * Clinical: Follow-up visits with physical consciousness, amnesia, or altered checks and ne
Slide 13: Clear Regulatory Pathway
Clear Regulatory A thorough regulatory process ensures trial integrity, while diligent preparation de-risks the U.S. pathway and positions positive Phase 2a results to provide a strong rationale for an IND submission. Phase 2 Regulatory Foundation Built Near Term Milestones 2026: Data & U.S. Expansi
Slide 14: Scalable Platform for Pipeline Expansion
Scalable Platform for Pipeline Expansion Possible Future CNS Therapeutic Applications: . z Ppiicatior Technology Platform * Proprietary intranasal delivery system with broad applications * Same technology applicable across multiple neurological conditions Market Context * Nasal delivery market proje
Slide 15: Comparable Measures of Value
Comparable Measures of Value Alpha aut nGen) a Cognition NYSE American: OGEN Nasdaq: ACOG $3.8M market cap $132M $0.91 share price $6.06 Intranasal formulation Concussion/mTBI for cognitive impairment with mTBI Phase 2 ready Preclinical; approved drug for AD NYSE American: NSRX $63M $7.35 Intranasal
Slide 16: Value-Creating Near-Term Milestones
* Final HREC amendment approval enabling clinical site onboarding * Phase 2a clinical trial initiation with first patient dosed in Australia Value-Creating Near-Term . . Phase 2a data readout from Australia trials IND submission to FDA for U.S. based Phase 2 clinical trials Continued Al-driven pipel
Slide 17: Brain-First Recovery
Brain-First Recovery™ Unlocking the Brain’s Capacity for Healing- One Breakthrough at a Time Oragenics | NYSE American: OGEN 18